123 related articles for article (PubMed ID: 21322116)
1. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
Cheng HL; Huang HJ; Ou BY; Chow NH; Chen YW; Tzai TS; Wu CJ; Chen SH
Proteomics Clin Appl; 2011 Apr; 5(3-4):121-32. PubMed ID: 21322116
[TBL] [Abstract][Full Text] [Related]
2. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
3. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
4. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
5. [Tree analysis pattern of mass spectral urine profiles in differential diagnosis of bladder transitional cell carcinoma].
Wu DL; Zhang YF; Guan M; Liu WW; Xu YM; Jin SB; Zhang J; Jin CR; Lü Y
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):274-7. PubMed ID: 17760254
[TBL] [Abstract][Full Text] [Related]
6. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
7. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.
Jayapalan JJ; Ng KL; Razack AH; Hashim OH
Electrophoresis; 2012 Jul; 33(12):1855-62. PubMed ID: 22740474
[TBL] [Abstract][Full Text] [Related]
9. Influence of blood sampling on protein profiling and pattern analysis using matrix-assisted laser desorption/ionisation mass spectrometry.
Pelzer AE; Feuerstein I; Fuchsberger C; Ongarello S; Bektic J; Schwentner C; Klocker H; Bartsch G; Bonn GK
BJU Int; 2007 Mar; 99(3):658-62. PubMed ID: 17407520
[TBL] [Abstract][Full Text] [Related]
10. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry.
Yu KH; Rustgi AK; Blair IA
J Proteome Res; 2005; 4(5):1742-51. PubMed ID: 16212428
[TBL] [Abstract][Full Text] [Related]
11. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
12. Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer.
Lu HB; Zhou JH; Ma YY; Lu HL; Tang YL; Zhang QY; Zhao CH
Jpn J Clin Oncol; 2010 Apr; 40(4):336-42. PubMed ID: 20089528
[TBL] [Abstract][Full Text] [Related]
13. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
14. Semi-targeted plasma proteomics discovery workflow utilizing two-stage protein depletion and off-line LC-MALDI MS/MS.
Juhasz P; Lynch M; Sethuraman M; Campbell J; Hines W; Paniagua M; Song L; Kulkarni M; Adourian A; Guo Y; Li X; Martin S; Gordon N
J Proteome Res; 2011 Jan; 10(1):34-45. PubMed ID: 20936781
[TBL] [Abstract][Full Text] [Related]
15. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform.
Oh JH; Pan S; Zhang J; Gao J
Rapid Commun Mass Spectrom; 2010 Feb; 24(4):403-8. PubMed ID: 20069694
[TBL] [Abstract][Full Text] [Related]
16. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer.
Jou YJ; Lin CD; Lai CH; Chen CH; Kao JY; Chen SY; Tsai MH; Huang SH; Lin CW
Anal Chim Acta; 2010 Nov; 681(1-2):41-8. PubMed ID: 21035601
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
18. Biomarker discovery for kidney diseases by mass spectrometry.
Niwa T
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(2):148-53. PubMed ID: 18024247
[TBL] [Abstract][Full Text] [Related]
19. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
Sardana G; Diamandis EP
Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
[TBL] [Abstract][Full Text] [Related]
20. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
